TWD 14.35
(7.49%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 67.64 Million TWD | -11.43% |
2022 | 213.74 Million TWD | 1.53% |
2021 | 210.52 Million TWD | -2.47% |
2020 | 215.84 Million TWD | -27.92% |
2019 | 299.42 Million TWD | -7.56% |
2018 | 323.9 Million TWD | 10.71% |
2017 | 292.56 Million TWD | 16.23% |
2016 | 251.72 Million TWD | -6.48% |
2015 | 269.15 Million TWD | -22.56% |
2014 | 347.54 Million TWD | 45.44% |
2013 | 238.96 Million TWD | 55.64% |
2012 | 153.53 Million TWD | -24.78% |
2011 | 204.11 Million TWD | -10.47% |
2010 | 227.96 Million TWD | -10.73% |
2009 | 255.38 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 50.38 Million TWD | -18.23% |
2024 Q2 | 46.19 Million TWD | -8.33% |
2024 Q3 | 69.89 Million TWD | -66.26% |
2023 Q3 | 46.16 Million TWD | 1.14% |
2023 Q4 | 61.61 Million TWD | 33.46% |
2023 FY | 189.32 Million TWD | -11.43% |
2023 Q1 | 35.88 Million TWD | -48.28% |
2023 Q2 | 45.64 Million TWD | 27.2% |
2022 Q2 | 43.41 Million TWD | -21.44% |
2022 Q3 | 45.68 Million TWD | 5.23% |
2022 Q4 | 69.38 Million TWD | 51.88% |
2022 Q1 | 55.26 Million TWD | -14.63% |
2022 FY | 213.74 Million TWD | 1.53% |
2021 Q2 | 57.9 Million TWD | 20.21% |
2021 Q4 | 64.73 Million TWD | 62.98% |
2021 FY | 210.52 Million TWD | -2.47% |
2021 Q1 | 48.16 Million TWD | 2.18% |
2021 Q3 | 39.71 Million TWD | -31.4% |
2020 Q3 | 52.92 Million TWD | -7.0% |
2020 Q2 | 56.91 Million TWD | -3.31% |
2020 Q1 | 58.86 Million TWD | -43.66% |
2020 Q4 | 47.13 Million TWD | -10.94% |
2020 FY | 215.84 Million TWD | -27.92% |
2019 Q3 | 67.4 Million TWD | 8.09% |
2019 FY | 299.42 Million TWD | -7.56% |
2019 Q1 | 65.17 Million TWD | -43.23% |
2019 Q2 | 62.36 Million TWD | -4.31% |
2019 Q4 | 104.48 Million TWD | 55.0% |
2018 Q2 | 71.4 Million TWD | 3.54% |
2018 FY | 323.9 Million TWD | 10.71% |
2018 Q4 | 114.79 Million TWD | 67.03% |
2018 Q3 | 68.72 Million TWD | -3.75% |
2018 Q1 | 68.96 Million TWD | -41.62% |
2017 Q3 | 63.52 Million TWD | 18.68% |
2017 FY | 292.56 Million TWD | 16.23% |
2017 Q2 | 53.52 Million TWD | -6.71% |
2017 Q4 | 118.14 Million TWD | 85.98% |
2017 Q1 | 57.37 Million TWD | -6.78% |
2016 Q1 | 67.51 Million TWD | 32.08% |
2016 FY | 251.72 Million TWD | -6.48% |
2016 Q3 | 55.1 Million TWD | -18.42% |
2016 Q4 | 61.55 Million TWD | 11.69% |
2016 Q2 | 67.54 Million TWD | 0.05% |
2015 Q1 | 85.39 Million TWD | -20.74% |
2015 Q2 | 72.64 Million TWD | -14.93% |
2015 Q3 | 59.98 Million TWD | -17.43% |
2015 Q4 | 51.11 Million TWD | -14.79% |
2015 FY | 269.15 Million TWD | -22.56% |
2014 Q4 | 107.74 Million TWD | 47.93% |
2014 Q2 | 123.05 Million TWD | 180.21% |
2014 FY | 347.54 Million TWD | 45.44% |
2014 Q1 | 43.91 Million TWD | -60.03% |
2014 Q3 | 72.83 Million TWD | -40.81% |
2013 Q3 | 52.94 Million TWD | 55.11% |
2013 Q1 | 42.02 Million TWD | 0.03% |
2013 FY | 238.96 Million TWD | 55.64% |
2013 Q4 | 109.86 Million TWD | 107.52% |
2013 Q2 | 34.13 Million TWD | -18.78% |
2012 Q3 | 46.81 Million TWD | 40.07% |
2012 Q2 | 33.42 Million TWD | 6.79% |
2012 Q1 | 31.29 Million TWD | -45.09% |
2012 Q4 | 42.01 Million TWD | -10.26% |
2012 FY | 153.53 Million TWD | -24.78% |
2011 Q1 | 49.47 Million TWD | -45.85% |
2011 FY | 204.11 Million TWD | -10.47% |
2011 Q4 | 56.99 Million TWD | -2.67% |
2011 Q3 | 58.55 Million TWD | 49.81% |
2011 Q2 | 39.08 Million TWD | -20.99% |
2010 FY | 227.96 Million TWD | -10.73% |
2010 Q4 | 91.35 Million TWD | 73.71% |
2010 Q1 | 37.98 Million TWD | 0.0% |
2010 Q2 | 46.04 Million TWD | 21.21% |
2010 Q3 | 52.58 Million TWD | 14.22% |
2009 FY | 255.38 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Grape King Bio Ltd | 6.03 Billion TWD | 98.88% |
Standard Chem & Pharm CO., LTD. | 1.46 Billion TWD | 95.385% |
Maywufa Company Ltd. | 854.37 Million TWD | 92.083% |
ScinoPharm Taiwan, Ltd. | 901.49 Million TWD | 92.497% |
Lotus Pharmaceutical Co., Ltd. | 4.48 Billion TWD | 98.49% |
LIWANLI Innovation Co., Ltd. | 54.86 Million TWD | -23.288% |
YungShin Global Holding Corporation | 2.04 Billion TWD | 96.697% |
SCI Pharmtech, Inc. | 190.02 Million TWD | 64.403% |
Formosa Laboratories, Inc. | 1.24 Billion TWD | 94.581% |
PharmaEssentia Corporation | 4.49 Billion TWD | 98.495% |
Bora Pharmaceuticals Co., LTD. | 1.74 Billion TWD | 96.117% |